Literature DB >> 23034211

Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level.

Kate Clouse1, Liesl Page-Shipp, Heather Dansey, Bridgette Moatlhodi, Lesley Scott, Jean Bassett, Wendy Stevens, Ian Sanne, Annelies Van Rie.   

Abstract

Xpert MTB/RIF (Xpert) offers rapid detection of Mycobacterium tuberculosis and rifampicin resistance. However, little is known about routine point-of-care (POC) use in high TB/HIV burden settings. We describe our experiences of launching Xpert as the POC, initial diagnostic for all TB suspects at a primary healthcare clinic in Johannesburg, South Africa. Noted important benefits of POC Xpert were fewer clinic visits, rapid detection of TB and rifampicin resistance, real-time assessment of accompanying household members of new TB cases, and increased staff motivation for TB screening. While Xpert results are available within 2 hours, actual turn-around time was longer for most patients because of sample preparation time and clinic congestion. Consequently, a GX4 instrument did not result in a 16-test capacity during an 8-hour working day, and some patients did not receive same-day results. Loss to follow-up was an unforeseen challenge, overcome by clinic flow changes, marking of clinic files, documenting patients' physical description and locating patients in the clinic by cell phone. Staff with high school education successfully performed the assay after minimal training. Human resource requirements were considerable, with a minimum of 2 staff needed to supervise sputum collection, process sputum, perform assays, and document results for an average of 15 TB suspects daily. POC placement of the instrument transferred logistical responsibilities to the clinic, including quality assurance, maintenance, stock control and cartridge disposal. POC use of Xpert is feasible at the primary healthcare level but must be accompanied by financial, operational and logistical support.

Entities:  

Mesh:

Year:  2012        PMID: 23034211     DOI: 10.7196/samj.5851

Source DB:  PubMed          Journal:  S Afr Med J


  34 in total

1.  Diagnostic delays and clinical decision making with centralized Xpert MTB/RIF testing in Durban, South Africa.

Authors:  Gabriel M Cohen; Paul K Drain; Farzad Noubary; Christie Cloete; Ingrid V Bassett
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

Review 2.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

Review 3.  HIV, tuberculosis, and noncommunicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care?

Authors:  Emily P Hyle; Kogieleum Naidoo; Amanda E Su; Wafaa M El-Sadr; Kenneth A Freedberg
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

4.  The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF.

Authors:  C F Hanrahan; K Clouse; J Bassett; L Mutunga; K Selibas; W Stevens; L Scott; I Sanne; A Van Rie
Journal:  Int J Tuberc Lung Dis       Date:  2015-07       Impact factor: 2.373

5.  Time to initiation of multidrug-resistant tuberculosis treatment and its relation with outcome in a high incidence district in Lima, Peru.

Authors:  L Otero; A De Orbegoso; A F Navarro; J Ríos; T Párraga; E Gotuzzo; C Seas; P Van der Stuyft
Journal:  Trop Med Int Health       Date:  2014-12-23       Impact factor: 2.622

6.  Has the utilisation of Xpert® MTB/RIF in Manicaland Province, Zimbabwe, improved with new guidance on whom to test?

Authors:  A Jokwiro; C Timire; A D Harries; P T Gwinji; A Mulema; K C Takarinda; P T Mafaune; C Sandy
Journal:  Public Health Action       Date:  2018-09-21

7.  Policy to practice: impact of GeneXpert MTB/RIF implementation on the TB spectrum of care in Lilongwe, Malawi.

Authors:  Kashmira S Chawla; Cecilia Kanyama; Abineli Mbewe; Mitch Matoga; Irving Hoffman; Jonathan Ngoma; Mina C Hosseinipour
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-05       Impact factor: 2.184

Review 8.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Authors:  Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

9.  Rollout of Xpert(®) MTB/RIF in Northwest Cambodia for the diagnosis of tuberculosis among PLHA.

Authors:  S C Auld; B K Moore; W P Killam; B Eng; K Nong; E C Pevzner; K K Eam; M T Eang; D Warren; S J Whitehead
Journal:  Public Health Action       Date:  2014-12-21

10.  Implementation of HIV and Tuberculosis Diagnostics: The Importance of Context.

Authors:  Joyelle K Dominique; Alberto A Ortiz-Osorno; Joseph Fitzgibbon; Devasena Gnanashanmugam; Christopher Gilpin; Timothy Tucker; Sheila Peel; Trevor Peter; Peter Kim; Steven Smith
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.